88

GW6471

88 Publications Verification

Cat. No.: HY-15372

CAS No.: 880635-03-0

Purity: 99.64%

Target:

PPAR Apoptosis

Research Areas:

Cancer

GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

78

Nintedanib

78 Cited Publications

Cat. No.: HY-50904

CAS No.: 656247-17-5

Synonyms: BIBF 1120

Target:

PDGFR VEGFR FGFR

Research Areas:

Cancer

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

78

Nintedanib esylate

78 Cited Publications

Cat. No.: HY-11106

CAS No.: 656247-18-6

Purity: 99.96%

Synonyms: BIBF 1120 esylate

Target:

PDGFR VEGFR FGFR

Research Areas:

Cancer

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

25

Molibresib besylate

25 Cited Publications

Cat. No.: HY-13032B

CAS No.: 1895049-20-3

Purity: 97.04%

Synonyms: GSK 525762C; I-BET 762 besylate

Target:

Epigenetic Reader Domain ERK

Research Areas:

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

21

SR-4835

21 Cited Publications

Cat. No.: HY-130250

CAS No.: 2387704-62-1

Purity: 99.64%

Target:

CDK Apoptosis

Research Areas:

Cancer

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

20

RMC-7977

20 Cited Publications

Cat. No.: HY-156498

CAS No.: 2765082-12-8

Purity: 99.48%

Target:

Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP

Research Areas:

Cancer

RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K_d = 195 nM) and KRAS (G12V) (K_d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS ^G12C cancer models, and demonstrates good tolerability across various RAS cancer models .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

13

Rebastinib

13 Cited Publications

Cat. No.: HY-13024

CAS No.: 1020172-07-9

Purity: 99.91%

Synonyms: DCC-2036

Target:

Bcr-Abl Cytochrome P450 Tie FOXO Src FLT3 Apoptosis

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC₅₀ values of 0.8 nM and 4 nM against Abl1 ^WT and Abl1 ^T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC₅₀ = 0.0533 μM) and CYP2C9 (IC₅₀ = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC₅₀ of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

AGX51

11 Cited Publications

Cat. No.: HY-129241

CAS No.: 330834-54-3

Purity: 99.33%

Target:

DNA/RNA Synthesis Reactive Oxygen Species (ROS)

Research Areas:

Neurological Disease Inflammation/Immunology Cancer

AGX51 is a pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist that disrupts ID-E protein interactions, thereby triggering ubiquitin-mediated proteasomal degradation of ID1, ID2, ID3 and ID4. AGX51 induces ROS production, G0/G1 cell cycle arrest, non-apoptotic cell death, and regulates EMT-related proteins. AGX51 reduces the proliferation, migration and myofibroblast differentiation of lung fibroblasts, alleviates pulmonary fibrosis, inhibits cancer cell viability and tumor growth, impairs neovascularization, and shows no obvious toxicity in mice. AGX51 can be used in research related to idiopathic pulmonary fibrosis, triple-negative breast cancer, breast cancer, pancreatic ductal adenocarcinoma, colorectal tumors, wet age-related macular degeneration and retinopathy of prematurity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

10

Sacituzumab

10 Cited Publications

Cat. No.: HY-P99045

CAS No.: 1796566-95-4

Synonyms: HRS7; hRS7

Target:

ADC Antibodies TROP2

Research Areas:

Cancer

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

9

Col003

9 Cited Publications

Cat. No.: HY-124817

CAS No.: 328565-16-8

Purity: 99.87%

Target:

HSP

Research Areas:

Inflammation/Immunology

Col003 is a selective and potent inhibitor of Hsp47 and competitively binds to the collagen binding site on Hsp47 (IC₅₀=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix. Col003 can be used for the investigation of fibrosis

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

LYN-1604

7 Cited Publications

Cat. No.: HY-101923

CAS No.: 2088939-99-3

Purity: 99.41%

Target:

ULK Autophagy Apoptosis

Research Areas:

Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

LYN-1604 dihydrochloride

7 Cited Publications

Cat. No.: HY-101923B

CAS No.: 2310109-38-5

Purity: 99.55%

Target:

ULK Autophagy Apoptosis

Research Areas:

Cancer

LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

Vanzacaftor

7 Cited Publications

Cat. No.: HY-145603

CAS No.: 2374124-49-7

Purity: 98.19%

Synonyms: VX-121

Target:

CFTR Chloride Channel

Research Areas:

Neurological Disease

Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

Iniparib

6 Cited Publications

Cat. No.: HY-12015

CAS No.: 160003-66-7

Purity: 99.74%

Synonyms: BSI-201; NSC-746045; IND-71677

Target:

PARP Influenza Virus

Research Areas:

Cancer

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

PD146176

6 Cited Publications

Cat. No.: HY-103157

CAS No.: 4079-26-9

Purity: 99.59%

Synonyms: NSC168807

Target:

Autophagy Ferroptosis

Research Areas:

Cardiovascular Disease

PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC₅₀=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

Compare

loading...